|
This funding will boost the US’s antibiotic manufacturing capacity, while helping to curb the threat of antimicrobial resistance (AMR) across America.
|
 |
|
The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress two of its bispecific ADC programmes to clinical development.
|
|
|
The fund’s resources allow it to invest up to €150m, helping businesses advance clinical development.
|
|
|
Everest Medicines will pay $250m in three instalments: $150m at closing, two $50m payments in 2028, 2029.
|
|
|
Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.
|
|
